Navigation Links
PURE Bioscience Announces Distribution Agreement With Orchem Corporation

NBA Hall of Fame Legend Oscar Robertson's Leading Specialty Chemical

Company will Market 'Powered by SDC' Spectrum 24 Disinfectant

SAN DIEGO, Calif., July 15 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced an agreement with Orchem Corporation for distribution of PURE's silver dihydrogen citrate (SDC)-based disinfectant under Orchem's Spectrum 24(TM) brand.


Owned by Hall of Fame basketball legend Oscar Robertson, Cincinnati-headquarted Orchem Corporation is the leading minority-owned specialty chemical manufacturer in the United States. Orchem has extensive expertise in proprietary product formulation, contract manufacturing and distribution services and provides state-of-the art proprietary formulated specialty cleaning and sanitizing solutions to the food, beverage, dairy processing, institutional, healthcare, general industrial, residential and commercial markets.

Michael L. Krall, president and CEO of PURE Bioscience said, "A focused marketing program and commitment to educating its customers make Orchem an ideal distributor for our SDC-based disinfectant. In addition, we appreciate the passion with which Orchem leads the specialty chemical industry in product quality and innovation while promoting safety and protecting the environment. Orchem has achieved outstanding and growing success in several key markets where SDC can provide immediate solutions and we look forward to a very successful launch of Spectrum 24."

According to Kenneth Munson, vice president sales and marketing for Orchem Corporation, Spectrum 24 will play a critical role in the battle against hospital acquired infections and diseases. Its rapid 30-second kill and 24-hour residual efficacy against a variety of dangerous pathogens and 2-minute kill of MRSA are unparalleled benefits.

Munson stated, "Adding Spectrum 24 to our comprehensive line of sanitation and instrument care products is creating a substantial amount of interest and excitement in the healthcare community. The patented SDC molecule used in Spectrum 24 is truly the most innovative disinfectant technology introduced to the healthcare market in over 30 years.

"Additionally, Oscar Robertson's longstanding business relationships in the field of professional and collegiate sports have greatly aided our efforts to safeguard athletes around the country. We are currently introducing a new pathogen reduction protocol for athletic fields, training rooms, locker rooms, and associated sports facilities in an effort to protect both professional as well as student athletes around the country."

Orchem has registered Spectrum 24 with the US EPA as a sub-registrant of PURE Bioscience and is currently undergoing registration in all 50 states. In accordance with the agreement, each bottle of Spectrum 24 features PURE's "Powered by SDC" logo. The contract also provides for increasing annual minimum purchases; other specific terms of the contract were not disclosed.

About Orchem Corporation

Orchem has extensive expertise in proprietary product formulation, contract manufacturing and distribution services and provides state-of-the-art proprietary formulated specialty cleaning and sanitizing solutions to the food, beverage, dairy processing, institutional, healthcare, general industrial, residential and commercial markets. Orchem manufactures a wide range of hard surface cleaners and sanitizers, infection control, and environmentally-safe enzyme cleaners, incorporating the latest blends of natural surfactants and eco-friendly cleaning chemistries.. Additionally, Orchem is capable of providing full turnkey private label manufacturing, distribution, and market support to entrepreneurial candidates looking for an opportunity to start their own business. For more information, please visit

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Investor Contact:

Paul G. Henning, Vice President

Cameron Associates

(212) 554-5462

SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
Breaking Biology News(10 mins):